Opus Genetics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.31 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.35, a 51.39% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.72, a 36.84% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $1.14, a 225.71% increase year-over-year.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.35, a 27.08% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $0.31, a 55.07% decline from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $0.69, a 28.13% decline from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2014 was $0.96, a 146.15% increase from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2013 was $0.39, a 4.88% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.31 10-K · filed 2017-02-24 | |||
| 2016-09-30 | $0.32 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | $0.33 10-Q · filed 2016-08-05 | |||
| 2016-03-31 | $0.35 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $0.69 10-K · filed 2016-03-14 | |||
| 2015-09-30 | $0.69 10-Q · filed 2015-11-02 | |||
| 2015-06-30 | $0.71 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $0.72 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $0.96 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $0.97 10-Q · filed 2015-11-02 | |||
| 2014-06-30 | $1.07 10-Q · filed 2015-08-07 | |||
| 2014-03-31 | $1.14 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | $0.39 10-K · filed 2015-03-16 | |||
| 2013-09-30 | $0.39 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | $0.37 10-Q · filed 2014-08-13 | |||
| 2013-03-31 | $0.35 10-Q · filed 2014-05-14 | |||
| 2012-12-31 | $0.41 10-K · filed 2014-03-21 | |||
| 2012-09-30 | $0.41 10-Q · filed 2013-11-13 | |||
| 2012-06-30 | $0.41 10-Q · filed 2013-08-12 | |||
| 2012-03-31 | $0.48 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $1.28 10-K · filed 2013-03-22 | |||
| 2011-09-30 | $1.39 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | $1.55 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |